Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

The undertaking to Delhi HC follows a patent infringement plea filed by the Danish drugmaker against Dr Reddy’s Laboratories ...

The Delhi High Court on May 29 recorded an undertaking from Dr. Reddy’s Laboratories that it will not sell the Ozempic like ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...